Rolapitant Improves QoL in Patients Receiving HEC or MEC

Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life.

Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life compared with a 5-HT3 receptor antagonist, dexamethasone, and placebo in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC), a study published in the journal Supportive Care in Cancer has shown.1

In those studies, investigators also assessed the impact of rolapitant on quality of life. Patients completed the Functional Living Index-Emesis (FLIE) questionnaire on day 6 of cycle 1; FLIE total score, as well as nausea and vomiting domain scores and the proportion of patients with no impact on daily life, were used as end points.

Inducing vasoconstriction in the scalp of patients with breast cancer undergoing chemotherapy effectively reduces the amount of drug that reaches the hair follicles and hair-cell metabolism, minimizing one of the ...